In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

International Journal of Antimicrobial Agents

Volumn 21, Issue 1, 2003, Pages 27-38

  Urbina, Julio A ^a   Payares, Gilberto ^b   Sanoja, Cristina ^b   Lira, Renee ^a   Romanha, Alvaro J ^c  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b FACULTAD DE CIENCIAS   (Venezuela)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

BMS 207,147; Chemotherapy; Inhibitors; Parasitic protozoa; Ravuconazole; Sterol biosynthesis; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; NITROFURAN; NITROIMIDAZOLE; RAVUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; EPIMASTIGOTE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARASITOLOGY; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; MICE; THIAZOLES; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0037220817     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00273-X     Document Type: Article

References (50)

1. World Health Organization. In: Thirteenth Programme Report, UNDP/World Bank/World Health Organization Programme for Research and Training in Tropical Diseases. Geneva: World Health Organization, 1997.
2. Croft S.L., Urbina J.A., Brun R. Chemotherapy of human leishmaniasis and trypanosomiasis. Hide G., Mottram J.C., Coombs G.H., Holmes P.H. Trypanomiasis and leishmaniasis. 1997;245-257 CAB International, London.
3. Cançado J.R. Terapêutica especifica. Pinto Dias J.C., Coura J.R. Clínica e terapêutica da doença de Chagas. 1997;323-351 Editora Fiocruz, Rio de Janeiro, Brasil.
4. Urbina J.A. Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med. 77:1999;332-338.
5. Urbina J.A. Parasitological cure of Chagas disease: is it possible?, is it relevant? Mem. Inst. Oswaldo Cruz. 94:(1):1999;349-355.
6. Sosa Estani S., Segura E.L. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines in Argentina. Mem. Inst. Oswaldo Cruz. 94:(1):1999;363-365.
7. Urbina J.A. Sterol biosynthesis inhibitors for Chagas' disease. Curr. Opin. Anti-infect. Inv. Drugs. 2:2000;40-46.
8. Urbina J.A. Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. 14:2001;733-741.
9. Urbina J.A. Chemotherapy of Chagas disease. Curr. Pharm. Des. 8:2002;287-295.
10. Urbina JA, Payares G, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against Trypanosoma cruzi strains, Int J Antimicrob Agents, in press.
11. Hata K., Kimura J., Miki H., Toyosawa T., Nakamura T., Katsu K. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. 40:1996;2237-2242.
12. Hata K., Kimura J., Miki H., Toyosawa T., Moriyama M., Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococcosis. Antimicrob. Agents Chemother. 40:1997;2243-2247.
13. Tsuruoka A., Kaku Y., Kakinuma H., et al. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives. Chem. Pharm. Bull. 46:1998;623-630.
14. Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42:1998;313-318.
15. Pfaller M.A., Messer S.A., Hollis R.J., et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592 and Voriconazole. Antimicrob. Agents Chemother. 42:1998;3242-3244.
16. Diekema D.J., Pfaller M.A., Messer S.A., et al. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 43:1999;2236-2239.
17. Pfaller M.A., Messer S.A., Gee S., et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37:1999;870-872.
18. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of bloodstream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35:1999;19-25.
19. Fung-Tomc J.C., White T.C., Minassian B., Huczko E., Bonner D.P. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. 35:1999;163-167.
20. Moore C.B., Walls C.M., Denning D.W. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and Amphotericin B. Antimicrob. Agents Chemother. 44:2000;441-443.
21. Yamazumi T., Pfaller M.A., Messer S.A., Houston A., Hollis R.J., Jones R.N. In vitro activities of ravuconazole (BMS-207147) against clinical isolates of Crytococcus neoformans. Antimicrob. Agents Chemother. 44:2000;2883-2886.
22. Roberts J., Schock K., Marino S., Andriole V.T. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44:2000;3381-3388.
23. Carrillo A.J., Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2001;2151-2153.
24. Clemons K.V., Stevens D.A. Efficay of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. 45:2001;3433-3436.
25. Clemons K.V., Martinez M., Calderon L., Stevens D.A. Efficacy or ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother. 46:2002;922-924.
26. Mosquera J., Denning D.W. Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46:2002;556-557.
27. Paphitou N.I., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., Rex J.H. In vitro antifungal susceptibilities in Trichosporon species. Antimicrob. Agents Chemother. 46:2002;1144-1146.
28. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:2002;1723-1727.
29. Olsen S.J., Mummaneni V., Rolan P., Norton J., Grasela D.M. Ravuconazole single ascending oral dose study in healthy in subjects. ICAAC Abst. 40:2000;838.
30. Grasela D.M., Olsen S.J., Mummaneni V., et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. ICAAC Abst. 40:2000;839.
31. Mikamo H., Shimamura Y., Uesugi K., Fukuyama N., Satoh M., Tamaya T. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. ICAAC Abst. 40:2000;1673.
32. Urbina J.A., Payares G., Molina J., et al. Cure of short- and long-term experimental Chagas Disease using D0870. Science. 273:1996;969-971.
33. Liendo A., Lazardi K., Urbina J.A. In vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother. 41:1998;197-205.
34. Urbina J.A., Payares G., Contreras L.M., et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1998;1771-1777.
35. Molina J., Martins-Filho O., Brener Z., Romanha A.J., Loebenberg D., Urbina J.A. Activity of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44:2000;150-155.
36. Molina J., Brener Z., Romanha A.J., Urbina J.A. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Effects of immunosuppresion. J. Antimicrob. Chemother. 46:2000;137-140.
37. Filardi L.S., Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:1987;755-759.
38. De Maio A., Urbina J.A. Trypanosoma (Schizotrypanum) cruzi: terminal oxidases in two growth phases in vitro. Acta Cient. Venez. 35:1984;136-141.
39. Vanden Bossche H. Chemotherapy of human fungal infections. Lyr H. Modern selective fungicides. Properties, applications, mechanism of action. 1995;431-484 Gustav Fisher Verlag, Jena.
40. Ritter W. Pharmacokinetics of azole compounds. Berg D., Pempel M. Sterol biosynthesis inhibitors. 1988;397-429 Ellis Horwood Ltd, Chichester, England.
41. Urbina J.A., Lazardi K., Aguirre T., Piras M.M., Piras R. Antiproliferative synergism of the allylamine SF-86327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32:1988;1237-1242.
42. Lazardi K., Urbina J.A., DeSouza W. Ultrastructural alterations induced by ICI 195,739, a bis triazole with strong antiproliferative action against Trypanosma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 35:1991;736-740.
43. Urbina J.A., Lira R., Visbal G., Bartrolí J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44:2000;2498-2502.
44. Shock K., Marino S., Baumgartner T., Andriole V. Efficacy of a new triazole, BMS-207147, in a model of invasive apergillosis in immunosuppressed, neutropenic rabbits. ICAAC Abst. 38:1998;J-54.
45. Moreira A.A.B., DeSouza H.B.W.T., Amato Neto V., et al. Avaliacão da atividade terapêutica do itraconazol nas infecçoes crônicas, experimental e humana, pelo Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo. 34:1992;177-180.
46. Brener Z., Cançado J.R., Galvão L.M., et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz. 88:1993;149-153.
47. McCabe R.E. Failure of ketoconazole to cure chronic murine Chagas disease. J. Infect. Dis. 158:1988;1408-1409.
48. Heel R.C., Brogden R.N., Carmine A., Morley P.A., Speight T.M., Avery G.S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 23:1982;1-36.
49. Molina J., Urbina J.A., Gref R., Brener Z., Rodrigues Junior J.M. Cure of experimental Chagas' disease by the bis-triazole D0870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J. Antimicrob. Chemother. 47:2001;101-104.
50. Araújo M.S.S., Molina J., Pereira M.E.S., Brener Z. Combination of drugs in the treatment of experimental Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz. 91:(1):1996;315.